27698544|t|Esomeprazole - or rabeprazole -based triple therapy eradicated Helicobacter pylori comparably regardless of clarithromycin susceptibility and CYP2C19 genotypes
27698544|a|The aim of this study was to assess the efficacy of esomeprazole -based triple therapy compared with rabeprazole -based triple therapy according to CYP2C19 genotype and clarithromycin susceptibility status for first-line eradication therapy of Helicobacter pylori (H. pylori) in Japan. We enrolled 219 H. pylori - infected patients, and randomly allocated patients to the EAC group (esomeprazole 20 mg, clarithromycin 200 mg, amoxicillin 750 mg for one week, with all drugs given twice daily) or RAC group (rabeprazole 10 mg, clarithromycin 200 mg, amoxicillin 750 mg for one week, with all drugs given twice daily). The H. pylori eradication rate according to the PP analyses was 75.0% (95% CI: 65.2-82.8%) in the EAC group and 71.4% (95% CI: 61.4-79.1%) in the RAC group. There were no statistically significant differences. The eradication rates of the clarithromycin -resistant /- sensitive strains were, respectively, 45.0% (95% CI: 30.7-60.2%)/98.0% (95% CI: 88.7-100%) in the EAC group and 39.5% (95% CI: 25.6-55.3%)/93.5% (95% CI: 81.9-98.4%) in the RAC group. The eradication rate of the clarithromycin - sensitive strains was significantly higher than that of the resistant strains in both groups. In conclusion, EAC and RAC therapies show a comparable efficacy regardless of the CYP2C19 genotype and clarithromycin susceptibility status in Japan.
27698544	0	12	Esomeprazole	T109,T121	C0937846
27698544	18	29	rabeprazole	T109,T121	C0378482
27698544	37	43	triple	T081	C0205174
27698544	44	51	therapy	T061	C0087111
27698544	63	82	Helicobacter pylori	T007	C0079488
27698544	94	104	regardless	T080	C3641650
27698544	108	122	clarithromycin	T109,T195	C0055856
27698544	123	137	susceptibility	T169	C1264642
27698544	142	149	CYP2C19	T028	C1332828
27698544	150	159	genotypes	T032	C0017431
27698544	176	181	study	T062	C2603343
27698544	189	195	assess	T052	C1516048
27698544	200	208	efficacy	T080	C1280519
27698544	212	224	esomeprazole	T109,T121	C0937846
27698544	232	238	triple	T081	C0205174
27698544	239	246	therapy	T061	C0087111
27698544	247	255	compared	T052	C1707455
27698544	261	272	rabeprazole	T109,T121	C0378482
27698544	280	286	triple	T081	C0205174
27698544	287	294	therapy	T061	C0087111
27698544	308	315	CYP2C19	T028	C1332828
27698544	316	324	genotype	T032	C0017431
27698544	329	343	clarithromycin	T109,T195	C0055856
27698544	344	358	susceptibility	T169	C1264642
27698544	359	365	status	T080	C0449438
27698544	381	423	eradication therapy of Helicobacter pylori	T061	C0559761
27698544	425	434	H. pylori	T007	C0079488
27698544	439	444	Japan	T083	C0022341
27698544	462	471	H. pylori	T007	C0079488
27698544	474	491	infected patients	T101	C0030705
27698544	497	505	randomly	T080	C0439605
27698544	506	515	allocated	T052	C1706778
27698544	516	524	patients	T101	C0030705
27698544	532	541	EAC group	T101	C0030705
27698544	543	555	esomeprazole	T109,T121	C0937846
27698544	563	577	clarithromycin	T109,T195	C0055856
27698544	586	597	amoxicillin	T109,T195	C0002645
27698544	613	617	week	T079	C0439230
27698544	628	633	drugs	T121	C0013227
27698544	634	639	given	T169	C1947971
27698544	640	651	twice daily	T079	C0585361
27698544	656	665	RAC group	T101	C0030705
27698544	667	678	rabeprazole	T109,T121	C0378482
27698544	686	700	clarithromycin	T109,T195	C0055856
27698544	709	720	amoxicillin	T109,T195	C0002645
27698544	736	740	week	T079	C0439230
27698544	751	756	drugs	T121	C0013227
27698544	757	762	given	T169	C1947971
27698544	763	774	twice daily	T079	C0585361
27698544	781	790	H. pylori	T007	C0079488
27698544	791	807	eradication rate	T081	C1521828
27698544	825	836	PP analyses	T062	C0936012
27698544	852	854	CI	T081	C0009667
27698544	875	884	EAC group	T101	C0030705
27698544	900	902	CI	T081	C0009667
27698544	923	932	RAC group	T101	C0030705
27698544	974	985	differences	T080	C1705242
27698544	991	1008	eradication rates	T081	C1521828
27698544	1016	1030	clarithromycin	T109,T195	C0055856
27698544	1016	1041	clarithromycin -resistant	T046	C0860039
27698544	1045	1054	sensitive	T169	C0332324
27698544	1055	1062	strains	T007	C0004611
27698544	1094	1096	CI	T081	C0009667
27698544	1121	1123	CI	T081	C0009667
27698544	1143	1152	EAC group	T101	C0030705
27698544	1168	1170	CI	T081	C0009667
27698544	1195	1197	CI	T081	C0009667
27698544	1218	1227	RAC group	T101	C0030705
27698544	1233	1249	eradication rate	T081	C1521828
27698544	1257	1271	clarithromycin	T109,T195	C0055856
27698544	1274	1283	sensitive	T169	C0332324
27698544	1284	1291	strains	T007	C0004611
27698544	1310	1316	higher	T080	C0205250
27698544	1334	1351	resistant strains	T046	C0860039
27698544	1355	1359	both	T080	C1706086
27698544	1360	1366	groups	T078	C0441833
27698544	1383	1386	EAC	T101	C0030705
27698544	1391	1394	RAC	T101	C0030705
27698544	1395	1404	therapies	T061	C0087111
27698544	1423	1431	efficacy	T080	C1280519
27698544	1432	1442	regardless	T080	C3641650
27698544	1450	1457	CYP2C19	T028	C1332828
27698544	1458	1466	genotype	T032	C0017431
27698544	1471	1485	clarithromycin	T109,T195	C0055856
27698544	1486	1500	susceptibility	T169	C1264642
27698544	1501	1507	status	T080	C0449438
27698544	1511	1516	Japan	T083	C0022341